Premium
Quantitation of anti‐hepatitic C virus antibodies in interferon‐treated patients by S29‐1/S4 ELISA
Author(s) -
Sato Atsushi,
Nakamura Haruji,
Sho Yukihiko,
Arima Terukatsu
Publication year - 1995
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.1890470307
Subject(s) - titer , antibody , virology , interferon , viremia , virus , hepatitis c virus , medicine , antibody titer , immunology
In 23 patients with chronic hepatitis C who have undergone interferon (IFN) treatment, quantitation of anti‐hepatitis C virus IgG antibodies by a second‐generation assay S29‐1/S4 ELISA [Sato et al. (1993): Microbiology and Immunology 37: 295‐304]. (anti‐S29‐1/S4) was compared with that of anti‐HCV core IgG antibodies (C22‐3, anti‐core) and the presence of viral RNA confirmed by the reverse transcription‐nested polymerase chain reaction (RT‐nested PCR). In 12 complete responders with loss of HCV‐RNA and normal alanine aminotransferase (ALT) levels at 6 months after therapy, IgG antibodies quantified by a second‐generation assay have decreased significantly at the end of treatment ( P < 0.05). Further significant reduction of anti‐S29‐1/S4 titers was observed at 6 months after therapy ( P < 0.01) as well as anti‐core antibodies ( P < 0.01). On the other hand, in 11 non‐responders with persistent or intermittent viremia at 6 months after therapy, no significant change in the level of anti‐S29‐l/S4 titers was observed, whereas anti‐core titers have decreased at the end of therapy ( P < 0.01). In contrast, both levels of anti‐S29‐1/S4 and anti‐core have increased at 6 months after treatment ( P < 0.05). It is concluded that, although it appears difficult to monitor the effect of virus clearance during IFN therapy, changes in anti‐S29‐l/S4 titers after IFN treatment correlate with virus clearance and with anti‐core titers. © Wiley‐Liss, Inc.